[go: up one dir, main page]

WO2016009303A1 - Associations de produits pharmaceutiques comprenant de la gabapentine ou de la prégabaline avec des inhibiteurs de nav1.7 - Google Patents

Associations de produits pharmaceutiques comprenant de la gabapentine ou de la prégabaline avec des inhibiteurs de nav1.7 Download PDF

Info

Publication number
WO2016009303A1
WO2016009303A1 PCT/IB2015/055100 IB2015055100W WO2016009303A1 WO 2016009303 A1 WO2016009303 A1 WO 2016009303A1 IB 2015055100 W IB2015055100 W IB 2015055100W WO 2016009303 A1 WO2016009303 A1 WO 2016009303A1
Authority
WO
WIPO (PCT)
Prior art keywords
pain
pharmaceutically acceptable
compound
acceptable salt
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2015/055100
Other languages
English (en)
Inventor
Douglas Scott KRAFTE
Rosemarie ROELOFFS
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Corp Belgium
Pfizer Corp SRL
Original Assignee
Pfizer Corp Belgium
Pfizer Corp SRL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Corp Belgium, Pfizer Corp SRL filed Critical Pfizer Corp Belgium
Publication of WO2016009303A1 publication Critical patent/WO2016009303A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics

Definitions

  • the invention relates to the treatment of pain using combinations of pharmaceutically active agents. More particularly, this invention relates to the use of combinations of an A/-thiazolyl-4-phenoxybenzenesulfonamide derivative and a second pharmaceutically active agent, and to pharmaceutical compositions containing them.
  • the A/-thiazolyl-4-phenoxybenzenesulfonamide derivatives that are the first component of the combinations of the present invention are modulators of the Na v 1.7 sodium channel.
  • the compounds are disclosed in International Patent Application PCT/IB2010/050033, published as WO2010/079443.
  • Voltage-gated sodium channels are found in all excitable cells including myocytes of muscle and neurons of the central and peripheral nervous system. In neuronal cells, sodium channels are primarily responsible for generating the rapid upstroke of the action potential. In this manner sodium channels are essential to the initiation and propagation of electrical signals in the nervous system. Proper and appropriate function of sodium channels is therefore necessary for normal function of the neuron. Consequently, aberrant sodium channel function is thought to underlie a variety of medical disorders (see Hubner C.A. , Jentsch T.J., Hum. Mol. Genet, 11 (20): 2435-45 (2002) for a general review of inherited ion channel disorders) including epilepsy (Yogeeswari et a/., Curr.
  • VGSC voltage-gated sodium channel alpha subunits
  • SCNx SCNx
  • SCNAx SCNx
  • Na v x.x The VGSC family has been phylogenetically divided into two subfamilies Na v 1.x (all but SCN6A) and Na v 2.x (SCN6A).
  • the Na v 1.x subfamily can be functionally subdivided into two groups, those which are sensitive to blocking by tetrodotoxin (TTX- sensitive or TTX-S) and those which are resistant to blocking by tetrodotoxin (TTX- resistant or TTX-R).
  • Na v 1.7 may play a key role in various pain states, including acute, inflammatory and/or neuropathic pain.
  • Na v 1.7 protein has been shown to accumulate in neuromas, particularly painful neuromas (Kretschmer et al., Acta. Neurochir. (Wien), 144(8): 803-10 (2002)).
  • Nav1.7 inhibitors are therefore potentially useful in the treatment of a wide range of disorders, particularly pain.
  • the second component of the combinations of the present invention is a pharmaceutically active agent selected from gabapentin and pregabalin.
  • Gabapentin (2-[1-(aminomethyl)cyclohexyl]acetic acid) and pregabalin ((S)-3- (aminomethy)-5-methylhexanoic acid) are ligands for the ⁇ 2 - ⁇ subunit of calcium channels. They have been reported to be effective in the treatment of neuropathic pain. Gabapentin is marketed under the brand name Neurontin and pregabalin is marketed under the brand name Lyrica.
  • a combination of a Na v 1.7 modulator and a modulator of activity at the alpha-2 delta subunit of calcium channels may afford a therapeutic regimen that provides: a greater efficacy; and/or the ability to use lower doses of the combination when compared to the individual agents; and/or an improved tolerability to the use of either agent alone.
  • the present invention provides a method of treating pain.
  • the present invention provides a method of treating pain comprising the administration to an individual in need of such treatment of a therapeutically effe (I)
  • said method further comprises the separate, sequential or simultaneous administration of a therapeutically effective amount of a second pharmaceutically active compound selected from gabapentin and pregabalin, or a pharmaceutically acceptable salt thereof.
  • the present invention provides the method of embodiment A1 E1 which consists essentially of the administration of a compound according to formula (I) and a second pharmaceutically active compound selected from gabapentin and pregabalin, or a pharmaceutically acceptable salt of one or both said compounds.
  • the present invention provides the method of embodiments A1 E1 or A1 E2, wherein the compound according to formula (I) is 4-[2-(5- amino-1 /-/-pyrazol-4-yl)-4-chlorophenoxy]-5-chloro-2-fluoro-/V-(1 ,3-thiazol-4- yl)benzenesulfonamide (l A ) or a pharmaceutically acceptable salt thereof.
  • the present invention provides the method of embodiments A1 E1 or A1 E2, wherein the compound according to formula (I) is 4-[2-(5- amino-1 /-/-pyrazol-4-yl)-4-(trifluoromethyl)-phenoxy]-5-chloro-2-fluoro-/ ⁇ /-(1 ,3-thiazol-4- yl)benzenesulfonamide (l B ) or a pharmaceutically acceptable salt thereof.
  • the present invention provides the method of any one of embodiments A1 E1, A1 E2, A1 E3 and A1 E4, wherein the second pharmaceutically active compound is gabapentin or a pharmaceutically acceptable salt thereof.
  • the present invention provides the method of any one of embodiments A1 E1 , A1 E2, A1 E3 and A1 E4, wherein the second pharmaceutically active compound is pregabalin or a pharmaceutically acceptable salt thereof.
  • the present invention provides the method of any one of embodiments A1 E1 , A1 E2, A1 E3, A1 E4, A1 E5 and A1 E6 wherein the compound according to formula (I) and the second pharmaceutically active compound are administered simultaneously.
  • the present invention provides the method of embodiment A1 E7, wherein the compound according to formula (I) and the second pharmaceutically active compound are administered together as a single pharmaceutical dosage form.
  • the present invention provides a combination of pharmaceutically active agents.
  • the present invention provides a combination comprising a compound according to formula (I) and a second pharmaceutically active compound, as defined in embodiments A1 E1 or A1 E2, or a pharmaceutically acceptable salt of one or both said compounds.
  • the present invention provides the combination according to embodiment A2E1 selected from:
  • the present invention provides a pharmaceutical dosage form.
  • the present invention provides a pharmaceutical dosage form comprising a compound according to formula (I) and a second pharmaceutically active compound, as defined in any one of embodiments A1 E1 , A1 E2, A1 E3, A1 E4, A1 E5 and A1E6, or a pharmaceutically acceptable salt of one or both said compounds; and one or more pharmaceutically acceptable excipients.
  • the present invention provides the pharmaceutical dosage form according to embodiment A3E1 for use as a medicament.
  • the present invention provides the pharmaceutical dosage form according to embodiments A3E1 or A3E2 for use in the treatment of pain.
  • the present invention provides a compound according to formula (I) as defined in embodiment A1 E1 , or a pharmaceutically acceptable salt thereof, for use in the treatment of pain, wherein the treatment further comprises the separate, sequential or simultaneous administration of a second pharmaceutically active compound as defined in embodiment A1 E1 , or a pharmaceutically acceptable salt thereof.
  • the present invention provides the compound according to aspect A4 for use in the treatment of pain, wherein the treatment further consists essentially of the separate, sequential or simultaneous administration of a second compound as defined in embodiment A1 E1 , or a pharmaceutically acceptable salt thereof.
  • the present invention provides a combination as defined in embodiment A2E1 or A2E2, or a pharmaceutically acceptable salt of one or both said compounds, for use in the treatment of pain.
  • the present invention provides the use of a compound according to formula (I) as defined in embodiment A1 E1 , or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for the treatment of pain, wherein the treatment further comprises the separate, sequential or simultaneous administration of of a second pharmaceutically active compound as defined in embodiment A1 E1 , or a pharmaceutically acceptable salt thereof.
  • the present invention provides the use of a compound according to aspect A6, wherein the treatment further consists essentially of the separate, sequential or simultaneous administration of a second compound as defined in claim 1 , or a pharmaceutically acceptable salt thereof.
  • the present invention provides the use of a combination as defined in embodiment A2E1 or A2E2, or a pharmaceutically acceptable salt of one or both said compounds, for the manufacture of a medicament for the treatment of pain.
  • the present invention provides a kit comprising:
  • a pharmaceutical dosage form comprising a compound according to formula (I) as defined in embodiment A1 E1 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient;
  • a pharmaceutical dosage form comprising a second pharmaceutically active compound as defined in embodiment A1 E1 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient; for use in the the treatment of pain.
  • the present invention provides the kit of aspect A8 for use in pain which consists essentially of pharmaceutical dosage forms (i) and (ii).
  • Fig 1 is a graphical representation of the degree of flinching over time for the high dose of pregabalin (Group 5).
  • Fig 2 is a graphical representation of the degree of flinching over time for the high dose of the compound of formula (l B ) (Group 3).
  • Fig 3 is a graphical representation of the degree of flinching over time for the high dose combination of the compound of formula (l B ) and pregabalin (Group 7).
  • Fig 4 is a graphical representation of the degree of flinching over time for the low dose of pregabalin (Group 4).
  • Fig 5 is a graphical representation of the degree of flinching over time for the high dose of the compound of formula (l B ) (Group 2).
  • Fig 6 is a graphical representation of the degree of flinching over time for the low dose combination of the compound of formula (l B ) and pregabalin (Group 6).
  • Fig 7.1 is a visualisation using posterior distribution plots on the log scale of the high dose combination during phase 2.
  • Fig 7.2 is a visualisation using posterior distribution plots on the log scale of the high dose combination during phase 2a.
  • the term “combinations of the invention” refers to a combination of a compound of formula (I) and a second pharmaceutically active compound, including:
  • treatment refers to palliative, curative and prophylactic treatment.
  • Treatment refers to palliative, curative and prophylactic treatment.
  • pain resulting from an injury or pathological condition
  • it will be understood that it is the pain that is being treated rather than the underlying cause of the pain.
  • Separatate administration refers to a therapeutic regimen in which the two agents are administered according to independent schedules. It includes the possibility that, where multiple doses of each agent are administered, then some of the doses may be taken together.
  • “Sequential” administration refers to a therapeutic regimen in which the two agents are administered according to the same schedule.
  • Simultaneous administration refers to a therapeutic regimen in which the two agents are administered together in a single action.
  • a method of treatment which consists essentially of the administration of a compound according to formula (I) and a second pharmaceutically active compound selected from gabapentin and pregabalin, or a pharmaceutically acceptable salt of one or both said compounds refers to a method consisting of the administration of two, and only two, pharmaceutically active agents.
  • kit of pharmaceutical dosage forms of a compound according to formula (I) and a second pharmaceutically active compound of a compound according to formula (I) and a second pharmaceutically active compound
  • the compounds of formula (I) may exist in tautomeric forms.
  • the aminopyrazole moiety may exist in one or more of the following forms:
  • the compounds of formula (I) are capable of forming pharmaceutically acceptable addition salts with acids, and these salts may be used in the invention.
  • Suitable acid addition salts are formed from acids which form non-toxic salts.
  • examples include the acetate, adipate, aspartate, benzoate, besylate, bicarbonate/carbonate, bisulphate/sulphate, borate, camsylate, citrate, cyclamate, edisylate, esylate, formate, fumarate, gluceptate, gluconate, glucuronate, hexafluorophosphate, hibenzate, hydrochloride/chloride, hydrobromide/bromide, hydroiodide/iodide, isethionate, lactate, malate, maleate, malonate, mesylate, methylsulphate, naphthylate, 2-napsylate, nicotinate, nitrate, orotate, oxalate, palmitate,
  • Hemisalts of acids and bases may also be formed, for example, hemisulphate salts.
  • Gabapentin and pregabalin have been reported to form salts with both acids and bases.
  • the aforementioned salts include ones wherein the counterion is optically active, for example d-lactate or l-lysine, or racemic, for example dl-tartrate or dl-arginine.
  • compositions of formula (I), gabapentin and pregabalin may be prepared by one or more of three methods: i) by reacting the compound of formula (I), gabapentin or pregabalin with the desired acid or base;
  • iii) by converting one salt of the compound of formula (I), gabapentin or pregabalin to another by reaction with an appropriate acid or base or by means of a suitable ion exchange column. All three reactions are typically carried out in solution.
  • the resulting salt may precipitate out and be collected by filtration or may be recovered by evaporation of the solvent. The degree of ionisation in the resulting salt may vary from completely ionised to almost non-ionised.
  • the compounds of formula (I), gabapentin and pregabalin, or pharmaceutically acceptable salts thereof may exist in both unsolvated and solvated forms.
  • 'solvate' is used herein to describe a molecular complex comprising a compound of formula (I), gabapentin or pregabalin, or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable solvent molcules, for example ethanol.
  • the term 'hydrate' is employed when said solvent is water.
  • Pharmaceutically acceptable solvates in accordance with the invention include those wherein the solvent of crystallization may be isotopically substituted, e.g. D 2 0, d 6 -acetone and d 6 -DMSO.
  • Isolated site hydrates are ones in which the water molcules are isolated from direct contact with each other by intervening organic molcules.
  • channel hydrates the water molcules lie in lattice channels where they are next to other water molcules.
  • metal-ion coordinated hydrates the water molcules are bonded to the metal ion.
  • the compounds of formula (I), gabapentin and pregabalin may exist in a continuum of solid states ranging from fully amorphous to fully crystalline.
  • the term 'amorphous' refers to a state in which the material lacks long range order at the molcular level and, depending upon temperature, may exhibit the physical properties of a solid or a liquid.
  • Such materials do not give distinctive X-ray diffraction patterns and, while exhibiting the properties of a solid, are more formally described as a liquid.
  • a change from solid to liquid properties occurs which is characterised by a change of state, typically second order ('glass transition').
  • 'crystalline' refers to a solid phase in which the material has a regular ordered internal structure at the molcular level and gives a distinctive X-ray diffraction pattern with defined peaks.
  • Such materials when heated sufficiently will also exhibit the properties of a liquid, but the change from solid to liquid is characterised by a phase change, typically first order ('melting point').
  • the compounds of formula (I) may be prepared by the methods disclosed in International Patent Application PCT/IB2010/050033, published as WO2010/079443, the disclosure of which is incorporated herein by reference, or by any other method known in the art for the preparation of compounds of analogous structure.
  • Compound (l A ) is Example 788 of WO2010/079443 and compound (l B ) is Example 1029 thereof.
  • Gabapentin and pregabalin are well known compounds and may be prepared by methods disclosed in the literature.
  • the compounds of formula (I), gabapentin and pregabalin may be obtained, for example, as solid plugs, powders, or films by methods such as precipitation, crystallization, freeze drying, spray drying, or evaporative drying. Microwave or radio frequency drying may be used for this purpose.
  • the compounds of formula (I), gabapentin and pregabalin may be administered separately or in combination. Generally, they will be administered as a formulation in association with one or more pharmaceutically acceptable excipients.
  • excipient' is used herein to describe any ingredient other than the compounds of formula (I), gabapentin and pregabalin.
  • the choice of excipient will to a large extent depend on factors such as the particular mode of administration, the effect of the excipient on solubility and stability, and the nature of the dosage form.
  • compositions suitable for the delivery of combinations of the present invention and methods for their preparation will be readily apparent to those skilled in the art. Such compositions and methods for their preparation may be found, for example, in "Remington's Pharmaceutical Sciences", 19th Edition (Mack Publishing Company, 1995).
  • Suitable modes of administration include oral, parenteral, topical, inhaled/intranasal, rectal/intravaginal, and ocular/aural administration.
  • gabapentin and pregabalin are administered separately they may be administered by different routes.
  • Formulations suitable for the aforementioned modes of administration may be formulated to be immediate and/or modified release.
  • Modified release formulations include delayed-, sustained-, pulsed-, controlled-, targeted and programmed release.
  • the compounds of formula (I), gabapentin and pregabalin, or combinations thereof, may be administered orally.
  • Oral administration may involve swallowing, so that the compound enters the gastrointestinal tract, or buccal or sublingual administration may be employed by which the compound enters the blood stream directly from the mouth.
  • Formulations suitable for oral administration include solid formulations such as tablets, capsules containing particulates, liquids, or powders, lozenges (including liquid-filled), chews, multi- and nano-particulates, gels, solid solution, liposome, films, ovules, sprays, liquid formulations and buccal/mucoadhesive patches.
  • Liquid formulations include suspensions, solutions, syrups and elixirs. Such formulations may be employed as fillers in soft or hard capsules and typically comprise a carrier, for example, water, ethanol, polyethylene glycol, propylene glycol, methylcellulose, or a suitable oil, and one or more emulsifying agents and/or suspending agents. Liquid formulations may also be prepared by the reconstitution of a solid, for example, from a sachet.
  • the compounds of formula (I), gabapentin and pregabalin, or combinations thereof, may also be used in fast-dissolving, fast-disintegrating dosage forms such as those described in Expert Opinion in Therapeutic Patents, 11. (6), 981-986, by Liang and Chen (2001).
  • the drug may make up from 1 weight % to 80 weight % of the dosage form, more typically from 5 weight % to 60 weight % of the dosage form.
  • tablets generally contain a disintegrant.
  • disintegrants include sodium starch glycolate, sodium carboxymethyl cellulose, calcium carboxymethyl cellulose, croscarmellose sodium, crospovidone, polyvinylpyrrolidone, methyl cellulose, microcrystalline cellulose, lower alkyl-substituted hydroxypropyl cellulose, starch, pregelatinised starch and sodium alginate.
  • the disintegrant will comprise from 1 weight % to 25 weight %, preferably from 5 weight % to 20 weight % of the dosage form.
  • Binders are generally used to impart cohesive qualities to a tablet formulation. Suitable binders include microcrystalline cellulose, gelatin, sugars, polyethylene glycol, natural and synthetic gums, polyvinylpyrrolidone, pregelatinised starch, hydroxypropyl cellulose and hydroxypropyl methylcellulose. Tablets may also contain diluents, such as lactose (monohydrate, spray-dried monohydrate, anhydrous and the like), mannitol, xylitol, dextrose, sucrose, sorbitol, microcrystalline cellulose, starch and dibasic calcium phosphate dihydrate.
  • lactose monohydrate, spray-dried monohydrate, anhydrous and the like
  • mannitol xylitol
  • dextrose sucrose
  • sorbitol microcrystalline cellulose
  • starch dibasic calcium phosphate dihydrate
  • Tablets may also optionally comprise surface active agents, such as sodium lauryl sulfate and polysorbate 80, and glidants such as silicon dioxide and talc.
  • surface active agents such as sodium lauryl sulfate and polysorbate 80
  • glidants such as silicon dioxide and talc.
  • surface active agents may comprise from 0.2 weight % to 5 weight % of the tablet, and glidants may comprise from 0.2 weight % to 1 weight % of the tablet.
  • Tablets also generally contain lubricants such as magnesium stearate, calcium stearate, zinc stearate, sodium stearyl fumarate, and mixtures of magnesium stearate with sodium lauryl sulphate.
  • Lubricants generally comprise from 0.25 weight % to 10 weight %, preferably from 0.5 weight % to 3 weight % of the tablet.
  • Other possible ingredients include anti-oxidants, colourants, flavouring agents, preservatives and taste-masking agents.
  • Exemplary tablets contain up to about 80% drug, from about 10 weight % to about 90 weight % binder, from about 0 weight % to about 85 weight % diluent, from about 2 weight % to about 10 weight % disintegrant, and from about 0.25 weight % to about 10 weight % lubricant.
  • Tablet blends may be compressed directly or by roller to form tablets. Tablet blends or portions of blends may alternatively be wet-, dry-, or melt- granulated, melt congealed, or extruded before tabletting.
  • the final formulation may comprise one or more layers and may be coated or uncoated; it may even be encapsulated. The formulation of tablets is discussed in "Pharmaceutical Dosage Forms: Tablets", Vol. 1 , by H. Lieberman and L. Lachman (Marcel Dekker, New York, 1980).
  • Suitable modified release formulations for the purposes of the invention are described in US Patent No. 6,106,864. Details of other suitable release technologies such as high energy dispersions and osmotic and coated particles are to be found in "Pharmaceutical Technology On-line", 25(2), 1-14, by Verma et al (2001). The use of chewing gum to achieve controlled release is described in WO 00/35298.
  • the compounds of formula (I), gabapentin and pregabalin, or combinations thereof, may also be administered directly into the blood stream, into muscle, or into an internal organ.
  • Suitable means for parenteral administration include intravenous, intraarterial, intraperitoneal, intrathecal, intraventricular, intraurethral, intrasternal, intracranial, intramuscular and subcutaneous.
  • Suitable devices for parenteral administration include needle (including microneedle) injectors, needle-free injectors and infusion techniques.
  • Parenteral formulations are typically aqueous solutions which may contain excipients such as salts, carbohydrates and buffering agents (preferably to a pH of from 3 to 9), but, for some applications, they may be more suitably formulated as a sterile nonaqueous solution or as a dried form to be used in conjunction with a suitable vehicle such as sterile, pyrogen-free water.
  • a suitable vehicle such as sterile, pyrogen-free water.
  • the preparation of parenteral formulations under sterile conditions for example, by lyophilisation, may readily be accomplished using standard pharmaceutical techniques well known to those skilled in the art.
  • the solubility of compounds of formula (I), gabapentin and pregabalin used in the preparation of parenteral solutions may be increased by the use of appropriate formulation techniques, such as the incorporation of solubility-enhancing agents.
  • Formulations for parenteral administration may be formulated to be immediate and/or modified release.
  • Modified release formulations include delayed-, sustained-, pulsed-, controlled-, targeted and programmed release.
  • compounds of the invention may be formulated as a solid, semi-solid, or thixotropic liquid for administration as an implanted depot providing modified release of the active compound.
  • examples of such formulations include drug-coated stents and poly(dl-lactic-coglycolic)acid (PGLA) microspheres.
  • the compounds of formula (I), gabapentin and pregabalin, or combinations thereof, may also be administered topically to the skin or mucosa, that is, dermally or transdermally.
  • Typical formulations for this purpose include gels, hydrogels, lotions, solutions, creams, ointments, dusting powders, dressings, foams, films, skin patches, wafers, implants, sponges, fibres, bandages and microemulsions. Liposomes may also be used.
  • Typical carriers include alcohol, water, mineral oil, liquid petrolatum, white petrolatum, glycerin, polyethylene glycol and propylene glycol.
  • Penetration enhancers may be incorporated - see, for example, J Pharm Sci, 88 (10), 955-958, by Finnin and Morgan (October 1999).
  • Other means of topical administration include delivery by electroporation, iontophoresis, phonophoresis, sonophoresis and microneedle or needle-free (e.g. PowderjectTM, BiojectTM, etc.) injection.
  • the compounds of formula (I), gabapentin and pregabalin, or combinations thereof, can also be administered intranasally or by inhalation, typically in the form of a dry powder (either alone, as a mixture, for example, in a dry blend with lactose, or as a mixed component particle, for example, mixed with phospholipids, such as phosphatidylcholine) from a dry powder inhaler or as an aerosol spray from a pressurised container, pump, spray, atomiser (preferably an atomiser using electrohydrodynamics to produce a fine mist), or nebuliser, with or without the use of a suitable propellant, such as 1 , 1 , 1 ,2-tetrafluoroethane or 1 , 1 ,1 ,2,3,3,3- heptafluoropropane.
  • the powder may comprise a bioadhesive agent, for example, chitosan or cyclodextrin.
  • the pressurised container, pump, spray, atomizer, or nebuliser contains a solution or suspension of the compound of formula (I), gabapentin or pregabalin, or a combination thereof, comprising, for example: ethanol, aqueous ethanol, or a suitable alternative agent for dispersing, solubilising, or extending release of the active; a propellant(s) as solvent; and an optional surfactant, such as sorbitan trioleate, oleic acid, or an oligolactic acid.
  • the drug product Prior to use in a dry powder or suspension formulation, the drug product is micronised to a size suitable for delivery by inhalation (typically less than 5 microns). This may be achieved by any appropriate comminuting method, such as spiral jet milling, fluid bed jet milling, supercritical fluid processing to form nanoparticles, high pressure homogenisation, or spray drying.
  • comminuting method such as spiral jet milling, fluid bed jet milling, supercritical fluid processing to form nanoparticles, high pressure homogenisation, or spray drying.
  • Capsules made, for example, from gelatin or hydroxypropylmethylcellulose
  • blisters and cartridges for use in an inhaler or insufflator may be formulated to contain a powder mix of the compound of the invention, a suitable powder base such as lactose or starch and a performance modifier such as l-leucine, mannitol, or magnesium stearate.
  • the lactose may be anhydrous or in the form of the monohydrate, preferably the latter.
  • Other suitable excipients include dextran, glucose, maltose, sorbitol, xylitol, fructose, sucrose and trehalose.
  • a suitable solution formulation for use in an atomiser using electrohydrodynamics to produce a fine mist may contain from ⁇ g to 20mg of the compounds of formula (I), gabapentin or pregabalin per actuation and the actuation volume may vary from 1 ⁇ to 100 ⁇ .
  • a typical formulation may comprise a compound of formula (I), propylene glycol, sterile water, ethanol and sodium chloride.
  • Alternative solvents which may be used instead of propylene glycol include glycerol and polyethylene glycol.
  • Suitable flavours, such as menthol and levomenthol, or sweeteners, such as saccharin or saccharin sodium, may be added to those formulations of the invention intended for inhaled/intranasal administration.
  • the dosage unit is determined by means of a valve which delivers a metered amount.
  • Units in accordance with the invention are typically arranged to administer a metered dose or "puff" containing from ⁇ g to 100mg of the compounds of formula (I), gabapentin or pregabalin.
  • the overall daily dose will typically be in the range ⁇ g to 200mg which may be administered in a single dose or, more usually, as divided doses throughout the day.
  • the compounds of formula (I), gabapentin and pregabalin, or combinations thereof, may be administered rectally or vaginally, for example, in the form of a suppository, pessary, microbicide, vaginal ring or enema.
  • Cocoa butter is a traditional suppository base, but various alternatives may be used as appropriate.
  • the compounds of formula (I), gabapentin and pregabalin, or combinations thereof, may also be administered directly to the eye or ear, typically in the form of drops of a micronised suspension or solution in isotonic, pH-adjusted, sterile saline.
  • Other formulations suitable for ocular and aural administration include ointments, biodegradable (e.g. absorbable gel sponges, collagen) and non-biodegradable (e.g. silicone) implants, wafers, lenses and particulate or vesicular systems, such as niosomes or liposomes.
  • a polymer such as crossed-linked polyacrylic acid, polyvinylalcohol, hyaluronic acid, a cellulosic polymer, for example, hydroxypropylmethylcellulose, hydroxyethylcellulose, or methyl cellulose, or a heteropolysaccharide polymer, for example, gelan gum, may be incorporated together with a preservative, such as benzalkonium chloride.
  • a preservative such as benzalkonium chloride.
  • Such formulations may also be delivered by iontophoresis.
  • the compounds of formula (I), gabapentin and pregabalin may be combined with soluble macromolcular entities, such as cyclodextrin and suitable derivatives thereof or polyethylene glycol-containing polymers, in order to improve their solubility, dissolution rate, taste-masking, bioavailability and/or stability for use in any of the aforementioned modes of administration.
  • Drug-cyclodextrin complexes for example, are found to be generally useful for most dosage forms and administration routes. Both inclusion and non-inclusion complexes may be used.
  • the cyclodextrin may be used as an auxiliary additive, i.e. as a carrier, diluent, or solubiliser.
  • the total daily dose of the compounds of formula (I) is typically in the range 10mg to 5g, such as 100mg to 3g, for example 250mg to 2g depending, of course, on the mode of administration and efficacy.
  • the total daily dose of gabapentin is typically in the range 200mg to 3g, such as 500mg to 2.5g, for example 900mg to 1.8g.
  • the total daily dose of pregabalin is typically in the range 50mg to 1 g, such as 150mg to 750mg, for example 300mg to 600mg.
  • oral administration may require a total daily dose of from 300mg to 2g of a compound of formula (I) and from 750mg to 2g of gabapentin, or from 150mg to 600mg of pregabalin.
  • the total daily dose may be administered in single or divided doses and may, at the physician's discretion, fall outside of the typical range given herein. These dosages are based on an average human subject having a weight of about 60kg to 70kg. The physician will readily be able to determine doses for subjects whose weight falls outside this range, such as infants and the elderly. Disorders for which the combinations of the invention are indicated include pain. Pain may be either acute or chronic and additionally may be of central and/or peripheral origin. Pain may be of a neuropathic and/or nociceptive and/or inflammatory nature, such as pain affecting either the somatic or visceral systems, as well as dysfunctional pain affecting multiple systems.
  • Physiological pain is an important protective mechanism designed to warn of danger from potentially injurious stimuli from the external environment.
  • the system operates through a specific set of primary sensory neurones and is activated by noxious stimuli via peripheral transducing mechanisms (see Meyer et al., 2006, Wall and Melzack's Textbook of Pain (5 Ed), Chapter"!).
  • These sensory fibres are known as nociceptors, and are characteristically small diameter axons with slow conduction velocities, of which there are two main types, A-delta fibres (myelinated) and C fibres (non-myelinated).
  • Nociceptors encode the intensity, duration and quality of noxious stimulus and by virtue of their topographically organised projection to the spinal cord, the location of the stimulus.
  • the activity generated by nociceptor input is transferred, after complex processing in the dorsal horn, either directly, or via brain stem relay nuclei, to the ventrobasal thalamus and then on to the cortex, where the sensation of
  • Pain may generally be classified as acute or chronic. Acute pain begins suddenly and is short-lived (usually twelve weeks or less). It is usually, although not always, associated with a specific cause such as a defined injury, is often sharp and severe and can result from numerous origins such as surgery, dental work, a strain or a sprain. Acute pain does not generally result in any persistent psychological response. When a substantial injury occurs to body tissue, via disease or trauma, the characteristics of nociceptor activation may be altered such that there is sensitisation in the periphery, locally around the injury and centrally where the nociceptors terminate. These effects lead to a hightened sensation of pain. In acute pain these mechanisms can be useful, in promoting protective behaviours which may better enable repair processes to take place.
  • Such symptoms can include: 1) spontaneous pain which may be dull, burning, or stabbing; 2) exaggerated pain responses to noxious stimuli (hyperalgesia); and 3) pain produced by normally innocuous stimuli (allodynia) (Meyer et al., 2006, Wall and Melzack's Textbook of Pain (5 th Ed), Chapterl).
  • patients suffering from various forms of acute and chronic pain may have similar symptoms, the underlying mechanisms may be different and may, therefore, require different treatment strategies.
  • pain can also be broadly categorized into: nociceptive pain, affecting either the somatic or visceral systems, which can be inflammatory in nature (associated with tissue damage and the infiltration of immune cells); or neuropathic pain.
  • Nociceptive pain can be defined as the process by which intense thermal, mechanical, or chemical stimuli are detected by a subpopulation of peripheral nerve fibers, called nociceptors, and can be induced by tissue injury or by intense stimuli with the potential to cause injury. Pain afferents are activated by transduction of stimuli by nociceptors at the site of injury and activate neurons in the spinal cord at the level of their termination. This is then relayed up the spinal tracts to the brain where pain is perceived (Meyer et al., 2006, Wall and Melzack's Textbook of Pain (5 th Ed), Chapterl).
  • Myelinated A-delta fibres transmit rapidly and are responsible for sharp and stabbing pain sensations, whilst unmyelinated C fibres transmit at a slower rate and convey a dull or aching pain.
  • Moderate to severe acute nociceptive pain is a prominent feature of pain from strains/sprains, burns, myocardial infarction and acute pancreatitis, post-operative pain (pain following any type of surgical procedure), posttraumatic pain, pain associated with gout, cancer pain and back pain.
  • Cancer pain may be chronic pain such as tumour related pain (e.g. bone pain, headache, facial pain or visceral pain) or pain associated with cancer therapy (e.g. in response to chemotherapy, immunotherapy, hormonal therapy or radiotherapy).
  • Back pain may be due to herniated or ruptured intervertabral discs or abnormalities of the lumber facet joints, sacroiliac joints, paraspinal muscles or the posterior longitudinal ligament. Back pain may resolve naturally but in some patients, where it lasts over 12 weeks, it becomes a chronic condition which can be particularly debilitating. Nociceptive pain can also be related to inflammatory states. The inflammatory process is a complex series of biochemical and cellular events, activated in response to tissue injury or the presence of foreign substances, which results in swelling and pain (McMahon et al., 2006, Wall and Melzack's Textbook of Pain (5 th Ed), Chapter3). A common inflammatory condition assoiciated with pain is arthritis.
  • OA osteoarthritis
  • degenerative joint disease Lawrence et al., 2008, Arthritis Rheum, 58, 15-35
  • Arthritis has a significant impact on psychosocial and physical function and is known to be the leading cause of disability in later life.
  • Rheumatoid arthritis is an immune-mediated, chronic, inflammatory polyarthritis disease, mainly affecting peripheral synovial joints. It is one of the commonest chronic inflammatory conditions in developed countries and is a major cause of pain.
  • visceral pain results from the activation of nociceptors of the thoracic, pelvic, or abdominal organs (Bielefeldt and Gebhart, 2006, Wall and Melzack's Textbook of Pain (5 th Ed), Chapter48). This includes the reproductive organs, spleen, liver, gastrointestinal and urinary tracts, airway structures, cardiovascular system and other organs contained within the abdominal cavity.
  • visceral pain refers to pain associated with conditions of such organs, such as painful bladder syndrome, interstitial cystitis, prostatitis, ulcerative colitis, Crohn's disease, renal colic, irritable bowl syndrome, endometriosis and dysmenorrhea!
  • Neuropathic pain is currently defined as pain arising as a direct consequence of a lesion or disease affecting the somatosensory system. Nerve damage can be caused by trauma and disease and thus the term 'neuropathic pain' encompasses many disorders with diverse aetiologies. These include, but are not limited to, peripheral neuropathy, diabetic neuropathy, post herpetic neuralgia, trigeminal neuralgia, back pain, cancer neuropathy, HIV neuropathy, phantom limb pain, carpal tunnel syndrome, central post- stroke pain and pain associated with chronic alcoholism, hypothyroidism, uremia, multiple sclerosis, spinal cord injury, Parkinson's disease, epilepsy and vitamin deficiency. Neuropathic pain is pathological as it has no protective role.
  • neuropathic pain are difficult to treat, as they are often heterogeneous even between patients with the same disease (Dworkin, 2009, Am J Med, 122, S1-S2; Geber et al., 2009, Am J Med, 122, S3-S12; Haanpaa et al., 2009, Am J Med, 122, S13-S21).
  • spontaneous pain which can be continuous, and paroxysmal or abnormal evoked pain, such as hyperalgesia (increased sensitivity to a noxious stimulus) and allodynia (sensitivity to a normally innocuous stimulus).
  • some types of pain have multiple aetiologies and thus can be classified in more than one area, e.g. back pain, cancer pain and even migaine headaches may include both nociceptive and neuropathic components.
  • fibromyalgia and chronic regional pain syndrome which are often described as dysfunctional pain states e.g. fibromyalgia or complex regional pain syndrome (Woolf, 2010, J Clin Invest, 120, 3742-3744), but which are included in classifications of chronic pain states (Classification of Chronic Pain, available at http://www.iasp-pain.org).
  • the combinations of the invention may optionally be used in combination with one or more further pharmacologically active compounds. Such combinations offer the possibility of further significant advantages, including patient compliance, ease of dosing and synergistic activity.
  • the combination of the invention may be administered simultaneously, sequentially or separately in combination with the other therapeutic agent or agents.
  • Useful further pharmacologically active agents include one or more agents selected from:
  • a selective Nav1.3 channel modulator such as a compound disclosed in WO2008/118758;
  • a selective Nav1.8 channel modulator such as a compound disclosed in WO2013/1 14250;
  • a compound which modulates activity at more than one Nav channel including a non-selective modulator such as bupivacaine, carbamazepine, lamotrigine, lidocaine, mexiletine or phenytoin;
  • NGF nerve growth factor
  • an agent that binds to NGF and inhibits NGF biological activity and/or downstream pathway(s) mediated by NGF signaling e.g. tanezumab
  • TrkA antagonist or a p75 antagoinsist e.g. tanezumab
  • an agent that inhibits downstream signaling in regard to NGF stimulated TrkA or P75 signalling e.g. tanezumab
  • TrkA antagonist or a p75 antagoinsist e.g. tanezumab
  • an agent that inhibits downstream signaling in regard to NGF stimulated TrkA or P75 signalling e.g. tanezumab
  • an agent that binds to nerve growth factor (NGF) e.g. tanezumab, fasinumab or fulranumab
  • nerve growth factor e.g. tanezumab, fasinumab or fulranumab
  • BDNF brain-derived neurotrophic factor
  • NT-3 neurotrophin-3
  • NT-4 neurotrophin-4
  • a compound which increases the levels of endocannabinoid such as a compound with fatty acid amid hydrolase inhibitory (FAAH) or monoacylglycerol lipase (MAGL) activity;
  • FAAH fatty acid amid hydrolase inhibitory
  • AML monoacylglycerol lipase
  • an analgesic in particular paracetamol
  • an opioid analgesic such as: buprenorphine, butorphanol, cocaine, codeine, dihydrocodeine, fentanyl, heroin, hydrocodone, hydromorphone, levallorphan levorphanol, meperidine, methadone, morphine, nalmefene, nalorphine, naloxone, naltrexone, nalbuphine, oxycodone, oxymorphone, propoxyphene or pentazocine;
  • an opioid analgesic such as: buprenorphine, butorphanol, cocaine, codeine, dihydrocodeine, fentanyl, heroin, hydrocodone, hydromorphone, levallorphan levorphanol, meperidine, methadone, morphine, nalmefene, nalorphine, naloxone, naltrexone, nalbuphine, oxycodone, oxymorphone, propoxyphene or pen
  • an opioid analgesic which preferentially stimulates a specific intracellular pathway, for example G-protein as opposed to beta arrestin recruitment, such as TRV130; an opioid analgesic with additional pharmacology, such as: noradrenaline (norepinephrine) reuptake inhibitory (NRI) activity, e.g. tapentadol; serotonin and norepinephrine reuptake inhibitory (SNRI) activity, e.g. tramadol; or nociceptin receptor (NOP) agonist activity, such as GRT6005;
  • NRI noradrenaline
  • SNRI serotonin and norepinephrine reuptake inhibitory
  • NOP nociceptin receptor
  • NSAID nonsteroidal antiinflammatory drug
  • COX non-selective cyclooxygenase
  • COX non-selective cyclooxygenase
  • a non-selective cyclooxygenase inhibitor e.g. aspirin, diclofenac, diflusinal, etodolac, fenbufen, fenoprofen, flufenisal, flurbiprofen, ibuprofen, indomethacin, ketoprofen, ketorolac, meclofenamic acid, mefenamic acid, meloxicam, nabumetone, naproxen, nimesulide, nitroflurbiprofen, olsalazine, oxaprozin, phenylbutazone, piroxicam, sulfasalazine, sulindac, tolmetin or zomepirac; or a COX
  • EP4 prostaglandin E2 subtype 4
  • microsomal prostaglandin E synthase type 1 (mPGES-1) inhibitor a microsomal prostaglandin E synthase type 1 (mPGES-1) inhibitor
  • a sedative such as glutethimide, meprobamate, methaqualone or dichloralphenazone;
  • a GABAA modulator with broad subtype modulatory effects mediated via the benzodiazepine binding site such as chlordiazepoxide, alprazolam, diazepam, lorazepam, oxazepam, temazepam, triazolam, clonazepam or clobazam;
  • GABAA modulator acting via alternative binding sites on the receptor, such as barbiturates, e.g. amobarbital, aprobarbital, butabital, mephobarbital, methohexital, pentobarbital, phenobartital, secobarbital, or thiopental; neurosteroids such as alphaxalone, alphadolone or ganaxolone; ⁇ -subunit ligands, such as etifoxine; or ⁇ - preferring ligands, such as gaboxadol;
  • barbiturates e.g. amobarbital, aprobarbital, butabital, mephobarbital, methohexital, pentobarbital, phenobartital, secobarbital, or thiopental
  • neurosteroids such as alphaxalone, alphadolone or ganaxolone
  • ⁇ -subunit ligands such as
  • a skeletal muscle relaxant e.g. baclofen, carisoprodol, chlorzoxazone, cyclobenzaprine, metaxolone, methocarbamol or orphrenadine;
  • glutamate receptor antagonist or negative allosteric modulator such as an NMDA receptor antagonist, e.g. dextromethorphan, dextrorphan, ketamine or, memantine; or an mGluR antagonist or modulator;
  • an alpha-adrenergic such as clonidine, guanfacine or dexmetatomidine
  • beta-adrenergic such as propranolol
  • a tricyclic antidepressant e.g. desipramine, imipramine, amitriptyline or nortriptyline
  • a tachykinin (NK) antagonist such as aprepitant or maropitant
  • a muscarinic antagonist e.g oxybutynin, tolterodine, propiverine, tropsium chloride, darifenacin, solifenacin, temiverine and ipratropium;
  • a cholinergic (nicotinic) analgesic such as ispronicline (TC-1734), varenicline or nicotine;
  • TRPV1 Transient Receptor Potential V1 (TRPV1) receptor agonist (e.g. resinferatoxin or capsaicin) or antagonist (e.g. capsazepine or mavatrap);
  • TRPV1 receptor agonist e.g. resinferatoxin or capsaicin
  • antagonist e.g. capsazepine or mavatrap
  • TRPA1 receptor agonist e.g. cinnamaldehyde or mustard oil
  • antagonist e.g. GRC17536 or CB-625
  • TRPM8 Transient Receptor Potential M8 (TRPM8) receptor agonist (e.g. menthol or icilin) or antagonist;
  • TRPV3 Transient Receptor Potential V3
  • ⁇ a corticosteroid such as dexamethasone
  • a 5-HT receptor agonist or antagonist particularly a 5-HTIB/ID agonist, such as eletriptan, sumatriptan, naratriptan, zolmitriptan or rizatriptan;
  • a PDEV inhibitor such sildenafil, tadalafil or vardenafil
  • an alpha-2-delta ligand such as gabapentin, gabapentin enacarbil or pregabalin, ;
  • SRI serotonin reuptake inhibitor
  • sertraline demethylsertraline
  • fluoxetine norfluoxetine
  • fluvoxamine paroxetine
  • citalopram desmethylcitalopram
  • escitalopram d,l-fenfluramine
  • femoxetine ifoxetine
  • cyanodothiepin litoxetine
  • nefazodone cericlamine and trazodone
  • anNRI such as maprotiline, lofepramine, mirtazepine, oxaprotiline, fezolamine, tomoxetine, mianserin, buproprion, buproprion metabolite hydroxybuproprion, nomifensine and viloxazine, especially a selective noradrenaline reuptake inhibitor such as reboxetine;
  • an SNRI such as venlafaxine, O-desmethylvenlafaxine, clomipramine, desmethylclomipramine, duloxetine, milnacipran and imipramine;
  • iNOS inducible nitric oxide synthase
  • a 5-lipoxygenase inhibitor such as zileuton
  • a potassium channel opener or positive modulator such as an opener or positive modulator of KCNQ/Kv7 (e.g. retigabine or flupirtine), a G protein-coupled inwardly- rectifying potassium channel (GIRK), a calcium-activated potassium channel (Kca) or a potassium voltage-gated channel such as a member of subfamily A (e.g. Kv1.1), subfamily B (e.g. Kv2.2) or subfamily K (e.g. TASK, TREK or TRESK);
  • subfamily A e.g. Kv1.1
  • subfamily B e.g. Kv2.2
  • subfamily K e.g. TASK, TREK or TRESK
  • a P2X 3 receptor antagonist e.g. AF219 or an antagonist of a receptor which contains as one of its subunits the P2X 3 subunit, such as a P2X 2 /3 heteromeric receptor;
  • T-type a Cav3.2 calcium channel blocker (T-type), such as ethosuximide.
  • the metabolism of the compounds of the invention includes oxidative processes carried out by P450 (CYP450) enzymes, particularly CYP 3A4 and conjugation by UDP glucuronosyl transferase and sulphating enzymes.
  • P450 CYP450
  • agents that may be used to increase the exposure of a patient to a compound of the present invention are those that can act as inhibitors of at least one isoform of the cytochrome P450 (CYP450) enzymes.
  • the isoforms of CYP450 that may be beneficially inhibited include, but are not limited to, CYP1A2, CYP2D6, CYP2C9, CYP2C19 and CYP3A4.
  • Suitable agents that may be used to inhibit CYP 3A4 include ritonavir, saquinavir, ketoconazole, N-(3,4-difluorobenzyl)-N-methyl-2- ⁇ [(4- methoxypyridin-3-yl)amino]sulfonyl ⁇ benzamide and N-(1-(2-(5-(4-fluorobenzyl)-3- (pyridin-4-yl)-1 H-pyrazol-1-yl)acetyl)piperidin-4-yl)methanesulfonamide.
  • kits suitable for coadministration of the compositions may conveniently be combined in the form of a kit suitable for coadministration of the compositions.
  • the kit of the invention comprises two or more separate pharmaceutical compositions, at least one of which contains a compound of formula (I) and one of which contains gabapentin or pregabalin, and means for separately retaining said compositions, such as a container, divided bottle, or divided foil packet.
  • An example of such a kit is the familiar blister pack used for the packaging of tablets, capsules and the like.
  • the kit of the invention is particularly suitable for administering different dosage forms, for example, oral and parenteral, for administering the separate compositions at different dosage intervals, or for titrating the separate compositions against one another.
  • the kit typically comprises directions for administration and may be provided with a so-called memory aid.
  • mice Male CD-1 mice (Charles River, Raleigh, NC) weighing 27-36 grams on the day of dosing were housed five per cage. Animals had free access to food and water and were maintained on a 12: 12 hour light/dark schedule.
  • Compounds and dosing solutions The Compound of formula (l B ) and pregabalin were formulated as solutions in 0.5% methyl cellulose. The high and low dose combinations were formulated together in 0.5% methyl cellulose into a single suspension for oral dosing. Compounds were dosed via oral gavage at 10mL/kg.
  • mice were tested for paw movement responses to an injection of a 2.5% formalin solution (20 ⁇ in saline) using the Automated Nociception Analyzer (Yaksh et al., 2001).
  • This device uses a magnetic detection system to measure paw movements defined as flinches.
  • Small metal bands were attached to the left hind paw of mice just before placement into individual circular test chambers (4 mice per session) 60 minutes prior to formalin injection. Mice were orally administered test compounds 2 hours prior to formalin injection.
  • mice were injected with 20 ⁇ of 2.5% formalin subcutaneously on the dorsal surface of the left hind paw and placed in the test chambers. The instrument then recorded rapid foot movements counted in one minute bins continuously for 60 minutes.
  • Treatment groups were assigned to balance treatments across days and across test chambers.
  • mice were euthanized and blood and brain tissue were removed for bioanalysis of the compound of formula (l B ) and pregabalin levels.
  • mice One mouse was excluded from both the vehicle group and from the compound of formula (l B ) 30 mg/kg group because of an incomplete formalin injection. One mouse was excluded from the compound of formula (l B ) 100 mg/kg group because the metal paw band fell off during the course of the flinching study. One mouse was excluded from the pregabalin 30mg/kg group because it only received a partial dose of test compound.
  • Data analysis The total flinches were counted over particular time intervals or phases. The phases summarized in this study were:
  • Table 2.4 Pregabalin 10 mg/kg (Group 4)
  • Phase 2 and Phase 2a The high dose combination resulted in a significant additive effect in Phase 2 and Phase 2a (p ⁇ 0.01).
  • Phase 2 flinching was decreased by 30%, 40% and 69% by the compound of formula (l B ) 100 mg/kg, pregabalin 30 mg/kg and the combination dose, respectively.
  • Phase 2a flinching was decreased by 36%, 38% and 74% by the compound of formula (l B ) 100 mg/kg, pregabalin 30 mg/kg and the combination dose, respectively.
  • Clinical studies can examine single or multiple doses of either or both agents in exploratory pain endpoints in healthy volunteers or patients. Clinical studies can also be carried out in pain patient populations employing, for example, parallel group, cross-over or randomised withdrawal study designs.

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention concerne une méthode de traitement de la douleur comprenant l'administration séparée, séquentielle ou simultanée, à un individu ayant besoin d'un tel traitement, d'une quantité thérapeutiquement efficace d'un composé de formule (I) ou d'un sel pharmaceutiquement acceptable de celui-ci, pour laquelle Y est –Cl ou –CF3, ainsi que d'une quantité thérapeutiquement efficace de gabapentine ou de prégabaline, ou d'un sel pharmaceutiquement acceptable de ces dernières.
PCT/IB2015/055100 2014-07-17 2015-07-06 Associations de produits pharmaceutiques comprenant de la gabapentine ou de la prégabaline avec des inhibiteurs de nav1.7 Ceased WO2016009303A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462025553P 2014-07-17 2014-07-17
US62/025,553 2014-07-17

Publications (1)

Publication Number Publication Date
WO2016009303A1 true WO2016009303A1 (fr) 2016-01-21

Family

ID=53969384

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2015/055100 Ceased WO2016009303A1 (fr) 2014-07-17 2015-07-06 Associations de produits pharmaceutiques comprenant de la gabapentine ou de la prégabaline avec des inhibiteurs de nav1.7

Country Status (5)

Country Link
JP (1) JP2016029033A (fr)
AR (1) AR101227A1 (fr)
CA (1) CA2897306A1 (fr)
TW (1) TW201605439A (fr)
WO (1) WO2016009303A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017106409A1 (fr) * 2015-12-18 2017-06-22 Merck Sharp & Dohme Corp. Composés d'arylsulfonamide à liaisons diamino-alkylamino ayant une activité sélective vis-à-vis des canaux sodiques voltage-dépendants

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114073698B (zh) * 2020-08-20 2023-03-31 山西泰睿鑫科技有限公司 一种止痛止痒药物组合物及其应用方法
CN114288289A (zh) * 2022-02-17 2022-04-08 昆山彭济凯丰生物科技有限公司 具有镇痛和/或止痒功能的药物组合物及其应用

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991011172A1 (fr) 1990-01-23 1991-08-08 The University Of Kansas Derives de cyclodextrines presentant une solubilite aqueuse amelioree et utilisation de ceux-ci
WO1994002518A1 (fr) 1992-07-27 1994-02-03 The University Of Kansas Derives de cyclodextrines ayant une meilleure solubilite aqueuse et leur utilisation
WO1998055148A1 (fr) 1997-06-05 1998-12-10 Janssen Pharmaceutica N.V. Compositions pharmaceutiques comprenant des cyclodextrines
WO2000035298A1 (fr) 1996-11-27 2000-06-22 Wm. Wrigley Jr. Company Chewing-gum contenant des agents medicamenteux actifs
US6106864A (en) 1995-09-15 2000-08-22 Pfizer Inc. Pharmaceutical formulations containing darifenacin
WO2008118758A1 (fr) 2007-03-23 2008-10-02 Icagen, Inc. Inhibiteurs de canaux ioniques
WO2010079443A1 (fr) 2009-01-12 2010-07-15 Pfizer Limited Dérivés sulfonamides
WO2013114250A1 (fr) 2012-02-03 2013-08-08 Pfizer Inc. Dérivés d'imidazopyridine et de benziimidazole en tant que modulateurs du canal sodium

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991011172A1 (fr) 1990-01-23 1991-08-08 The University Of Kansas Derives de cyclodextrines presentant une solubilite aqueuse amelioree et utilisation de ceux-ci
WO1994002518A1 (fr) 1992-07-27 1994-02-03 The University Of Kansas Derives de cyclodextrines ayant une meilleure solubilite aqueuse et leur utilisation
US6106864A (en) 1995-09-15 2000-08-22 Pfizer Inc. Pharmaceutical formulations containing darifenacin
WO2000035298A1 (fr) 1996-11-27 2000-06-22 Wm. Wrigley Jr. Company Chewing-gum contenant des agents medicamenteux actifs
WO1998055148A1 (fr) 1997-06-05 1998-12-10 Janssen Pharmaceutica N.V. Compositions pharmaceutiques comprenant des cyclodextrines
WO2008118758A1 (fr) 2007-03-23 2008-10-02 Icagen, Inc. Inhibiteurs de canaux ioniques
WO2010079443A1 (fr) 2009-01-12 2010-07-15 Pfizer Limited Dérivés sulfonamides
WO2013114250A1 (fr) 2012-02-03 2013-08-08 Pfizer Inc. Dérivés d'imidazopyridine et de benziimidazole en tant que modulateurs du canal sodium

Non-Patent Citations (32)

* Cited by examiner, † Cited by third party
Title
"Remington's Pharmaceutical Sciences", 1995, MACK PUBLISHING COMPANY
AHMAD ET AL., HUM MOL GENET., vol. 16, no. 17, 1 December 2006 (2006-12-01), pages 2114 - 21
AZIZ ET AL., DIG DIS, vol. 27, no. 1, 2009, pages 31 - 41
BIELEFELDT; GEBHART: "Wall and Melzack's Textbook of Pain", 2006
CANNON, S.C., KIDNEY INT., vol. 57, no. 3, 2000, pages 772 - 9
CLASSIFICATION OF CHRONIC PAIN, Retrieved from the Internet <URL:http://www.iasp-pain.org>
COX, NATURE, vol. 444, no. 7121, 2006, pages 894 - 8
DWORKIN, AM J MED, vol. 122, 2009, pages S1 - S2
FERTLEMAN ET AL., NEURON, vol. 52, no. 5, 2006, pages 767 - 74
FINNIN; MORGAN, J PHARM SCI, vol. 88, no. 10, October 1999 (1999-10-01), pages 955 - 958
GEBER ET AL., AM J MED, vol. 122, 2009, pages S3 - S12
GOLDBERG ET AL., CLIN GENET., vol. 71, no. 4, 2007, pages 311 - 9
H. LIEBERMAN; L. LACHMAN: "Pharmaceutical Dosage Forms: Tablets", vol. 1, 1980, MARCEL DEKKER
HAANPAA ET AL., AM J MED, vol. 122, 2009, pages S13 - S21
HUBNER C.A.; JENTSCH T.J., HUM. MOL. GENET.,, vol. 11, no. 20, 2002, pages 2435 - 45
K. R. MORRIS: "Polymorphism in Pharmaceutical Solids", 1995, MARCEL DEKKER
KRETSCHMER ET AL., ACTA. NEUROCHIR. (WIEN),, vol. 144, no. 8, 2002, pages 803 - 10
LAWRENCE ET AL., ARTHRITIS RHEUM, vol. 58, 2008, pages 15 - 35
LEGROUX-CREPEL ET AL., ANN. DERMATOL VENEREOL.,, vol. 130, pages 429 - 433
LIANG; CHEN, EXPERT OPINION IN THERAPEUTIC PATENTS, vol. 11, no. 6, 2001, pages 981 - 986
MCMAHON ET AL.: "Wall and Melzack's Textbook of Pain", 2006
MEYER ET AL.: "Wall and Melzack's Textbook of Pain", 2006
NASSAR ET AL., PROC NATL ACAD SCI USA, vol. 101, no. 34, 2004, pages 12706 - 11
NOBLE D., PROC. NATL. ACAD. SCI. USA, vol. 99, no. 9, 2002, pages 5755 - 6
STAHL; WERMUTH: "Handbook of Pharmaceutical Salts: Properties, Selection, and Use", 2002, WILEY-VCH
VERMA ET AL., PHARMACEUTICAL TECHNOLOGY ON-LINE, vol. 25, no. 2, 2001, pages 1 - 14
WAXMAN, SG, NEUROLOGY, vol. 69, no. 6, 7 December 2006 (2006-12-07), pages 505 - 7
WOOD, J. N. ET AL., J. NEUROBIOL., vol. 61, no. 1, 2004, pages 55 - 71
WOOLF, J CLIN INVEST, vol. 120, 2010, pages 3742 - 3744
WOOLF; SALTER, SCIENCE, vol. 288, 2000, pages 1765 - 1768
YANG ET AL., J. MED. GENET.,, vol. 41, no. 3, 2004, pages 171 - 4
YOGEESWARI ET AL., CURR. DRUG TARGETS, vol. 5, no. 7, 2004, pages 589 - 602

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017106409A1 (fr) * 2015-12-18 2017-06-22 Merck Sharp & Dohme Corp. Composés d'arylsulfonamide à liaisons diamino-alkylamino ayant une activité sélective vis-à-vis des canaux sodiques voltage-dépendants
US10519147B2 (en) 2015-12-18 2019-12-31 Merck Sharp & Dohme Corp. Diamino-alkylamino-linked arylsulfonamide compounds with selective activity in voltage-gated sodium channels

Also Published As

Publication number Publication date
CA2897306A1 (fr) 2016-01-17
TW201605439A (zh) 2016-02-16
AR101227A1 (es) 2016-11-30
JP2016029033A (ja) 2016-03-03

Similar Documents

Publication Publication Date Title
ES2532356T3 (es) N-sulfonilbenzamidas como inhibidores de los canales de sodio dependientes de voltaje
JP5860045B2 (ja) 化合物
CA2861439C (fr) Derives d&#39;imidazopyridine et de benziimidazole en tant que modulateurs du canal sodium
ES2526541T3 (es) N-sulfonilbenzamidas como inhibidores de canales de sodio dependientes de voltaje
US20070191462A1 (en) Combination of A 5-HT(1) Receptor Agonist and an Alpha-2-Delta Ligand for the Treatment of Migraine
CA2951497C (fr) Derives d&#39;imidazopyridazine utilises comme modulateurs de l&#39;activite des recepteurs gabaa
CA2804716A1 (fr) Composes chimiques
CA3213593A1 (fr) Inhibiteurs de sos1 et inhibiteurs de ras destines a etre utilises dans le traitement de la douleur
CA2860553A1 (fr) N-aminosulfonylbenzamides
JP5069415B2 (ja) 結晶形態のイミダゾール誘導体
KR20070009746A (ko) 통증의 치료에 사용하기 위한 알파-2-델타 리간드와ｐｄｅｖ 억제제의 상승작용 조합물
AU2011200717A1 (en) Combinations comprising alpha-2-delta ligands and serotonin / noradrenaline re-uptake inhibitors
WO2012120398A1 (fr) Dérivés de carboxamide substitués par aryle en tant que modulateurs de trpm8
WO2016009303A1 (fr) Associations de produits pharmaceutiques comprenant de la gabapentine ou de la prégabaline avec des inhibiteurs de nav1.7
US20090227562A1 (en) Combination of a Selective Noradrenaline Reuptake Unhibitor and a PDEV Inhibitor
US10538523B2 (en) 4-(biphen-3-yl)-1H-pyrazolo[3,4-c]pyridazine derivatives of formula (I) as GABA receptor modulators for use in the treatment of epilepsy and pain
TWI680761B (zh) 尿酸性或痛風性疾病的預防或治療
JP2008512436A (ja) 片頭痛治療用の５−ＨＴ（１）受容体アゴニストとα２δリガンドの組み合わせ
WO2016039660A1 (fr) Dérivés de 7-fluoro-8-chloro-5h- dibenzo[b,e] [1,4]diazépine et leur utilisation
US20080293746A1 (en) Combinations comprising pregabalin
TW201806601A (zh) σ受體配體在皰疹後遺疼痛中的用途
CN117940166A (zh) 用于治疗疼痛的sos1抑制剂和ras抑制剂
ZA200700129B (en) Combination of a selective noradrenaline reuptake inhibitor and a PDEV inhibitor
WO2009136375A1 (fr) Traitement de la cystite interstitielle

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15753999

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 15753999

Country of ref document: EP

Kind code of ref document: A1